Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

John J. Bissler(Cincinnati Children's Hospital Medical Center), J.C. Kingswood(Royal Sussex County Hospital), Elżbieta Radzikowska, Bernard A. Zonnenberg(University Medical Center Utrecht), Michael Frost(Minnesota Epilepsy Group), Е. Д. Белоусова, Matthias Sauter(LMU Klinikum), Norio Nonomura(Osaka University Hospital), Susanne Brakemeier(Charité - Universitätsmedizin Berlin), Petrus J. de Vries(University of Cape Town), Vicky Whittemore(National Institutes of Health), David Chen(Novartis (United States)), Tarek Sahmoud(Novartis (United States)), Gaurav Shah(Novartis (United States)), Jeremie Lincy(Novartis (Switzerland)), David Lebwohl(Novartis (United States)), Klemens Budde(Charité - Universitätsmedizin Berlin)
The Lancet
January 11, 2013
Cited by 878

Abstract


Related Papers

No related papers found

Powered by citation graph analysis